BioVersys AGXSWX:BIOV +1.17%4 Market Cap is CHF152.05 Mil as of Jun. 28, 2026. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100. Among 1,429 Biotechnology companies, BioVersys AG ranks better than 57.17% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioVersys AG's share price for the quarter that ended in Dec. 2025 was CHF24.4. BioVersys AG's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 5.85 Mil. Therefore, BioVersys AG's market cap for the quarter that ended in Dec. 2025 was CHF142.69 Mil.
BioVersys AG's quarterly market cap
increased
from Dec. 2024 (CHF0.00 Mil) to Jun. 2025 (CHF203.16 Mil) but then
declined
from Jun. 2025 (CHF203.16 Mil) to Dec. 2025 (CHF142.69 Mil).
BioVersys AG's annual market cap
stayed the same
from . 20 (CHF0.00 Mil) to Dec. 2024 (CHF0.00 Mil) but then
increased
from Dec. 2024 (CHF0.00 Mil) to Dec. 2025 (CHF142.69 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioVersys AG's Enterprise Value for Today is CHF91.27 Mil.
BioVersys AG (XSWX:BIOV) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioVersys AG Market Cap Related Terms
BioVersys AG Market Cap Historical Data
* Premium members only.
The historical data trend for BioVersys AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG Market Cap Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
Market Cap
0.00
142.69
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
Market Cap
0.00
0.00
203.16
142.69
XSWX:BIOV vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, BioVersys AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's Market Cap distribution charts can be found below:
* The bar in red indicates where BioVersys AG's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioVersys AG's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG (XSWX:BIOV) has a Market Cap of CHF152.05 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #612 out of 1429 companies in the Biotechnology industry, placing it in the top 42.8%.
Is BioVersys AG's Market Cap too high?
BioVersys AG's current Market Cap is CHF152.05 Mil. Based on the distribution chart, BioVersys AG ranks #612 out of 1429 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #612 out of 1429 companies for Market Cap. This puts BioVersys AG in the upper half of its industry. The industry median Market Cap is 112.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioVersys AG and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVersys AG's current Market Cap is CHF152.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Market Cap of CHF152.05 Mil. The current Market Cap is CHF152.05 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Market Cap is CHF152.05 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score
Get the complete analysis for XSWX:BIOV
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIOV has been successfully added to your 